GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | −1 |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | TD Waterhouse Canada Inc. | 42.01K | +624.7% | $7.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 3.41K | +22.8% | $564,045 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assetmark, Inc | $3.25M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 481 holders, 137.05M shares, $11.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 116 sh · $19,242
Director · 69 sh · $11,032
Director · 1.10K sh · $192,432
Director · 826 sh · $144,550
Director · 3.30K sh · $578,888
Director · 1.30K sh · $229,236
Director · 971 sh · $172,330
Director · 116 sh · $20,300
Officer · 7.74K sh · $1.38M
Officer · 4.00K sh · $632,193
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology